Ticker
ACRX

Price
1.99
Stock movement up
+- (%)
Company name
AcelRx Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Markedsværdi
16.31M
Ent værdi
24.35M
Pris/omsætning
10.73
Pris/bog
0.59
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
0.34
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-78.37%
3 års afkast
-61.69%
5 års afkast
-45.26%
10 års afkast
-33.12%
Senest opdateret: 2023-01-27

UDBYTTE

ACRX betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E0.34
Pris til OCF-
Pris til FCF-
Pris til EBITDA0.33
EV i forhold til EBITDA0.49

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning10.73
Pris til egenkapital0.59
EV i forhold til salg16.01

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier8.20M
EPS (TTM)6.41
FCF pr. aktie (TTM)-4.24

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)1.52M
Bruttofortjeneste (TTM)-1.94M
Driftsindkomst (TTM)-37.38M
Nettoindkomst (TTM)47.32M
EPS (TTM)6.41
EPS (1 år frem)-2.93

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-127.68%
Driftsmargin (TTM)-2457.26%
Fortjenstmargin (TTM)3111.24%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter12.73M
Nettotilgodehavender512.00K
Omsætningsaktiver i alt24.54M
Goodwill0.00
Immaterielle aktiver8.82M
Ejendomme, anlæg og udstyr0.00
Sum aktiver48.31M
Kreditor2.00M
Kortfristet/nuværende langsigtet gæld12.47M
Summen af kortfristede forpligtelser15.65M
Sum gæld20.77M
Aktionærernes egenkapital27.54M
Materielle nettoaktiver27.23M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-30.92M
Investeringsudgifter (TTM)344.00K
Fri pengestrøm (TTM)-31.27M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast171.82%
Afkast af aktiver97.95%
Afkast af investeret kapital128.64%
Kontant afkast af investeret kapital-84.99%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning2.10
Daglig høj2.14
Daglig lav1.95
Daglig volumen211K
Højeste gennem alle tider262.40
1 års analytiker estimat80.00
Beta0.26
EPS (TTM)6.41
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation8 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACRXS&P500
Nuværende prisfald fra top notering-99.24%-15.08%
Højeste prisfald-99.32%-56.47%
Højeste efterår dato9 Nov 20229 Mar 2009
Gennemsnitlig fald fra toppen-64.02%-11.49%
Gennemsnitlig tid til nyt højdepunkt115 days13 days
Maks. tid til nyt højdepunkt2397 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ACRX (AcelRx Pharmaceuticals Inc) company logo
Markedsværdi
16.31M
Markedsværdi kategori
Small-cap
Beskrivelse
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Personale
20
Investor relationer
-
SEC-indsendelser
Adm. direktør
Vincent J. Angotti
Land
USA
By
Redwood City
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript November 14, 2022 AcelRx Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.2....
29. december 2022
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settin...
27. december 2022
In this article, we discuss the 10 cheapest stocks with the biggest upside. If you want to read about some more cheapest stocks with the biggest upside, go directly to 5 Cheapest Stocks With Biggest U...
19. december 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
8. december 2022
AcelRx Pharmaceuticals ( NASDAQ:ACRX ) Third Quarter 2022 Results Key Financial Results Net loss: US$6.75m (loss...
17. november 2022
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto...
14. november 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
14. november 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Monday, November 1...
3. november 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
31. oktober 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
27. oktober 2022
Næste side